Literature DB >> 8548768

Genetic aberrations detected by comparative genomic hybridization are associated with clinical outcome in renal cell carcinoma.

H Moch1, J C Presti, G Sauter, N Buchholz, P Jordan, M J Mihatsch, F M Waldman.   

Abstract

The clinical behavior of renal cell carcinoma (RCC) cannot be predicted by histological and other markers. In this study, comparative genomic hybridization was used to evaluate whether the number of genomic aberrations has prognostic significance in 41 nonmetastatic clear cell RCC extending beyond the renal capsule. Losses were most prevalent at 3p (56%) and 9p and 13q (24% each). The number of DNA losses per tumor was associated with recurrence-free survival (P = 0.03). DNA gains most often involved chromosome 5q (17%) and chromosome 7 (15%). The number of DNA gains was not associated with clinical outcome. Loss of chromosome 9p was the only individual locus associated with recurrence (P = 0.04), suggesting that a tumor suppressor gene on chromosome 9p may play a role in RCC progression.

Entities:  

Mesh:

Year:  1996        PMID: 8548768

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  44 in total

1.  Early and late genetic changes in clear cell renal carcinoma.

Authors:  Holger Moch
Journal:  Urologe A       Date:  2004-09       Impact factor: 0.639

2.  Comparative genomic hybridization of malignant fibrous histiocytoma reveals a novel prognostic marker.

Authors:  M L Larramendy; M Tarkkanen; C Blomqvist; M Virolainen; T Wiklund; S Asko-Seljavaara; I Elomaa; S Knuutila
Journal:  Am J Pathol       Date:  1997-10       Impact factor: 4.307

Review 3.  Renal cell carcinoma deep sequencing: recent developments.

Authors:  Leslie J Farber; Kyle Furge; Bin Tean Teh
Journal:  Curr Oncol Rep       Date:  2012-06       Impact factor: 5.075

4.  CDKNA2A mutation analysis, protein expression, and deletion mapping of chromosome 9p in conventional clear-cell renal carcinomas: evidence for a second tumor suppressor gene proximal to CDKN2A.

Authors:  P Schraml; K Struckmann; R Bednar; W Fu; T Gasser; K Wilber; J Kononen; G Sauter; M J Mihatsch; H Moch
Journal:  Am J Pathol       Date:  2001-02       Impact factor: 4.307

5.  Chromosome 14q loss defines a molecular subtype of clear-cell renal cell carcinoma associated with poor prognosis.

Authors:  Federico A Monzon; Karla Alvarez; Lief Peterson; Luan Truong; Robert J Amato; Joan Hernandez-McClain; Nizar Tannir; Anil V Parwani; Eric Jonasch
Journal:  Mod Pathol       Date:  2011-07-01       Impact factor: 7.842

6.  Evaluation of the clonal relationship between primary and metastatic renal cell carcinoma by comparative genomic hybridization.

Authors:  H Bissig; J Richter; R Desper; V Meier; P Schraml; A A Schäffer; G Sauter; M J Mihatsch; H Moch
Journal:  Am J Pathol       Date:  1999-07       Impact factor: 4.307

7.  Monosomy of Chromosome 9 Is Associated With Higher Grade, Advanced Stage, and Adverse Outcome in Clear-cell Renal Cell Carcinoma.

Authors:  Reza Nejati; Shuanzeng Wei; Robert G Uzzo; Sahar Poureghbali; Jianming Pei; Jacqueline N Talarchek; Karen Ruth; Essel Dulaimi; Alexander Kutikov; Joseph R Testa; Tahseen Al-Saleem
Journal:  Clin Genitourin Cancer       Date:  2019-09-26       Impact factor: 2.872

Review 8.  Renal cell carcinoma.

Authors:  Paul Cairns
Journal:  Cancer Biomark       Date:  2010       Impact factor: 4.388

Review 9.  [Identification of VHL-associated changes in clear cell renal carcinoma: the application of combined genome and expression analyses].

Authors:  G Boysen; B Wollscheid; D Bausch-Fluck; P Schraml; H Moch
Journal:  Pathologe       Date:  2009-12       Impact factor: 1.011

10.  Loss of heterozygosity and copy number abnormality in clear cell renal cell carcinoma discovered by high-density affymetrix 10K single nucleotide polymorphism mapping array.

Authors:  Marieta I Toma; Marianne Grosser; Alexander Herr; Daniela E Aust; Axel Meye; Christian Hoefling; Susanne Fuessel; Daniela Wuttig; Manfred P Wirth; Gustavo B Baretton
Journal:  Neoplasia       Date:  2008-07       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.